Efficacy and safety of ClairYg？, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopenia

In the abstract of this article published in AJBR, an error occurred regarding the percentage of responders after one injection: 11/17 patients should be 65% and not 59%. This is correctly stated in the body of the article